

From the INTERNATIONAL PRELIMINARY EXAMINING

To:

LEE, Young-Pil

The Cheonghwa Building, 1571-18, Seocho-dong, Seocho-gu 137-874 Seoul Republic of Korea

PCT

NOTIFICATION OF TRANSMITTAL OF INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Rule 71.1)

Date of mailing (day/month/year)

11 OCTOBER 2004 (11.10.2004)

Applicant's or agent's file reference
YB-20069-PCT

IMPORTANT NOTIFICATION

International application No.

International filing date (day/month/year)

Priority date (day/months/year)

PCT/KR2003/001502

26 JULY 2003 (26.07.2003)

26 JULY 2002 (26.07.2002)

Applicant

YUHAN CORPORATION et al

- 1. The applicant is hereby notified that International Preliminary Examining Authority transmits here with the international preliminary examination report and its annexes, if any, established on the international application.
- 2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
- 3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report(but not of any annexes) and will transmit such translation to those Offices.

4. REMINDER

The applicant must enter the national phase before each elected office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details in the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

Name and mailing address of the IPEA/KR

(3)

Korean Intellectual Property Office 920 Dunsan-dong, Seo-gu, Daejeon 302-701, Republic of Korea

Facsimile No. 82-42-472-7140

Authorized officer

COMMISSIONER

Telephone No. 82-42-481-5207





PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Artcle 36 and Rule 70)

Applicant's or agent's file reference YB-20069-PCT	FOR FURTHER ACTION	SeeNotificationofTransmittalofInternationalPreliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/KR2003/001502	International filing date(day/mo 26 JULY 2003 (26.07.20		date (day/month/year) Y 2002 (26.07.2002)
International Patent Classification (IPC) of IPC7 C07D 405/12 Applicant YUHAN CORPORATION et a 1. This international preliminary examination and is transmitted to the applicant	al amination report has been preparaccording to Article 36.	red by this International F	Preliminary Examining Authority
2. This REPORT consists of a total of sheets, including this cover sheet. This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT). These annexes consist of a total ofsheets.			
3. This report contains indications relating to the following items: I X Basis of the report II Priority III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability IV Lack of unity of invention V X Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement VI Certain documents cited VII Certain defects in the international application VIII Certain observations on the international application			
Date of submission of the demand 26 JANUARY 2004		of completion of this report 06 OCTOBER 2004 (
Name and mailing address of the IPEA/ Korean Intellectual Propert 920 Dunsan-dong, Seo-gu, Republic of Korea Facsimile No. 82-42-472-7140	y Office Daejeon 302-701,	norized officer LEE, Mi Jeong phone No. 82-42-481-560	



INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International aplication No.

PCT/KR2003/001502

I.	Basis	of the report	
1.	With	regard to the elements of the international application:*	
	$\overline{\mathbf{X}}$	the international application as originally filed	·
		the description:	, as originally filed
		pages	, filed with the demand
		pages, filed with the letter of	
	\Box	the claims:	
		pages	as originally filed
		pages, as amended (together with an pages	y statment) under Article 19 , filed with the demand
		pages, filed with the letter of	
	\Box	the drawings:	
	ш	pages	_ , as originally filed
		pages, filed with the letter of	, filed with the demand
	\Box	the sequence listing part of the description:	
	ш	nages	, as originally filed
		pages	, filed with the demand
		pages, filed with the letter of	
2.	Wit	h regard to the language, all the elements marked above were available or furnished to this Auth	nority in the language in which
	the	international application was filed, unless otherwise indicated under this item.	
	The	se elements were available or furnished to this Authority in the following language	
İ		the language of a translation furnished for the purposes of international search (under Rule 23	3.1(b)).
	Ш	the language of publication of the international application (under Rule 48.3(b)).	' (' (1 1 1 55 2 4/
		the language of the translation furnished for the purposes of international preliminary exam or 55.3).	ination(under Rules 55.2 and
3	. Wi	th regard to any nucleotide and/or amino acid sequence disclosed in the international appleliminary examination was carried out on the basis of the sequence listing:	lication, the international
		contained inthe international application in written form.	
		filed together with the international application in computer readable form.	
		furnished subsequently to this Authority in written form.	
	\Box	furnished subsequently to this Authority in computer readable form	
	\Box	The statement that the subsequently furnished written sequence listing does not go be	eyond the disc losure in the
		international applicationas as filed has been furinshed. The statement that the information recorded in computer readable form is identical to the	written sequence listing has
	Ш	been furnished.	Witten Sequence iisang nas
_		The amendments have resulted in the cancellation of:	
*	لــا	· ·	
		the description, pages the claims, Nos.	
		the drawings, sheet	
5.		the drawings, sheet	
-		This report has been established as if (some of) the amendments had not been made, since go beyond the disclosure as filed, as indicated in the Supplemental Box(Rule 70.2(c)).**	e they have been considered to
*	in th	lacement sheets which have been furnished to the receiving Office in response to an invitation u his opinion as "originally filed." and are not annexed to this report since they do not contain 70.17).	nder Article 14 are referred to n amendments (Rules 70.16
	** Any	replacement sheet containing such amendments must be referred to under item I and annexed	to this report.



	L
libd	tional aplication No
PCT/K	R2003/001502

V.	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability;
	citations and explanations supporting such statement

1.	Statement			
	Novelty (N)	Claims	1 - 10	YES
		Claims		NO
	Inventive step (IS)	Claims	1 - 10	YES
		Claims		NO
	Industrial applicability (IA)	Claims	1 - 10	YES
		Claims		NO
	Industrial applicability (IA)	Claims	1 - 10	YES

2. Citations and explanations (Rule 70.7)

The following documents are referred to in this report:

D1: WO 0038687 A (6 July 2000)

D2: WO 9808802 A (5 March 1998)

D3: KR 1077201 A (17 August 2001)

D4: WO 0048993 A (24 August 2000)

1. Novelty and Inventive Step

The present invention relates to 1-phenylpiperidine-3-one derivatives of formula (I) having a highly selective inhibitory activity against cathepsin K which is a member of the family of cysteine proteases and pharmaceutical compositions containing the same as an active ingredient.

- D1 discloses 4-amino-azepan-3-one derivatives which inhibit proteases, particularly cathepsin K.
- D2 discloses cyclopentanone or cyclohexanone derivatives which are inhibitors of cysteine proteases, particularly cathepsin K.
- D3 discloses 4-hydroxylamino-3-cyclobutene-1,2-dione derivatives having inhibitory effect against cysteine proteases, particularly cathepsins.

D4 discloses arylaminoalkylamide derivatives as a cathepsin K inhibitor.

None of D1-D4 discloses 1-phenylpiperidine-3-one derivatives of formula (I) in the present invention.

D1 seems to be the closest prior art to the present invention in terms of the backbone structures of the active compounds. However, they differ in that the compounds of formula (I) have a "cyclohexyl" instead of an "aryl" in D1 and a 6-membered ring including N instead of 7-membered ring including N in D1. Those who skilled in the art would not be able to expect the changes in the backbone structure of the cathepsin K inhibitors in the present invention from D1.

Therefore, claims 1-10 of the present invention are considered to be novel and involve an inventive step over D1-D4 [Article 33(2) and 33(3) PCT].

(Continued on Supplemental Sheet.)



Ir ational aplication No.

PCT/KR2003/001502

Supplemental Box (To be used when the space in any of the preceding boxes is a Continuation of:	
Continuation of: Box V.	
2. Industrial Applicability	
The subject-matter of claims 1-10 appears to be indus	trially applicable [Article 33(4) PCT].
	·
•	